Quick Answer
Ovid Therapeutics Inc. reported Research And Development Expense of $25.58 million for the year ending 2025.
- Ovid Therapeutics Inc. showed a decrease of -30.4% in Research And Development Expense from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $1.13 million | Q2 2016: $1.77 million | Q3 2016: $2.70 million | Q1 2017: $31.28 million | Q2 2017: $6.07 million | Q3 2017: $5.90 million | Q1 2018: $8.47 million | Q2 2018: $8.12 million | Q3 2018: $8.54 million | Q1 2019: $9.34 million | Q2 2019: $9.12 million | Q3 2019: $11.60 million | Q1 2020: $14.63 million | Q2 2020: $16.03 million | Q3 2020: $15.88 million | Q1 2021: $16.25 million | Q2 2021: $7.68 million | Q3 2021: $4.92 million | Q1 2022: $7.83 million | Q2 2022: $6.05 million | Q3 2022: $5.18 million | Q1 2023: $6.62 million | Q2 2023: $6.00 million | Q3 2023: $5.33 million | Q1 2024: $10.40 million | Q2 2024: $12.58 million | Q3 2024: $7.86 million | Q1 2025: $6.66 million | Q2 2025: $6.47 million | Q3 2025: $5.87 million.
- Over the full 11 years of available data (2015 to 2025), Ovid Therapeutics Inc.'s Research And Development Expense has grown by 286.9%.
- Historical annual values: Fiscal year 2025: $25.58 million | Fiscal year 2024: $36.77 million | Fiscal year 2023: $28.59 million | Fiscal year 2022: $24.62 million | Fiscal year 2021: $46.94 million | Fiscal year 2020: $63.42 million | Fiscal year 2019: $42.16 million | Fiscal year 2018: $33.79 million | Fiscal year 2017: $49.97 million | Fiscal year 2016: $9.59 million | Fiscal year 2015: $6.61 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: